AQY2-2 Antibody

What is AQP2 and why is it important in physiological research?

AQP2 belongs to a family of membrane proteins that facilitate water passage through biological membranes. The aquaporin family consists of 13 members (AQP0 to AQP12), with AQP2 being part of the classical aquaporins that are solely permeated by water, unlike aquaglyceroporins that allow passage of water and other small solutes such as glycerol . AQP2 expression is largely confined to the kidney, particularly in renal collecting ducts where it performs a key role in water absorption and urine concentration . Its physiological significance is underscored by the fact that mutations in the AQP2 gene produce hereditary nephrogenic diabetes insipidus, a disorder resulting in excretion of large volumes of dilute urine .

What is the structural organization of the AQP2 protein that researchers should be aware of when selecting antibodies?

AQP2 presents a conserved structure of six transmembrane domains with intracellular N- and C-termini . The functional channel exists as a tetramer, but each subunit contains its own separate pore, resulting in a functional channel unit with four pores . When selecting antibodies, researchers should consider whether they need antibodies targeting intracellular epitopes (such as the C-terminus) or extracellular domains, depending on their experimental design. For instance, the Anti-Aquaporin 2 Antibody (#AQP-002) targets a peptide corresponding to amino acid residues 254-271 of rat AQP2, located at the intracellular C-terminus .

How does the regulation of AQP2 differ from other aquaporins?

AQP2 is unique among aquaporins as the only water channel directly regulated by vasopressin, which enhances its activity and promotes urine concentration . Under normal conditions, water homeostasis in the kidney is regulated through the anti-diuretic hormone vasopressin, which is secreted from the pituitary gland and transported to the kidney through the bloodstream . The activated vasopressin receptor induces an increase in intracellular cAMP and subsequent PKA activation, which phosphorylates AQP2 . This phosphorylation triggers the translocation of AQP2 channels from intracellular vesicles to the cell membrane, markedly increasing water permeability . This distinctive regulatory mechanism makes AQP2 a particularly interesting research target for studies on water balance regulation.

What are the optimal methods for detecting AQP2 in different experimental contexts?

AQP2 can be detected using various experimental techniques, with antibody-based methods being particularly effective. For western blotting, the Anti-Aquaporin 2 Antibody can be used at a dilution of 1:200 on rat kidney membranes . For immunohistochemistry on paraffin-embedded sections, a dilution of 1:100 is recommended for rat kidney sections, which produces intense staining in collecting ducts but not in thin segments of the loop of Henle . Mouse monoclonal antibodies like AQP2 Antibody (E-2) can detect AQP2 from mouse, rat, and human samples using western blotting, immunoprecipitation, immunofluorescence, immunohistochemistry, and ELISA . When designing experiments, researchers should consider which detection method aligns best with their research questions and ensure appropriate controls are included (such as preincubation with blocking peptides) .

How should experiments be designed to study AQP2 trafficking in response to vasopressin?

When studying AQP2 trafficking, researchers should consider both steady-state localization and dynamic movement upon stimulation. For steady-state analysis, immunofluorescence with confocal microscopy can provide general subcellular localization, though it lacks sufficient spatial resolution to identify specific subcellular compartments with certainty . For more detailed analysis, immunoisolation of AQP2-containing vesicles followed by proteomic analysis can identify compartment-specific marker proteins .

To study dynamic trafficking, researchers can design experiments where cells or tissues are exposed to vasopressin, followed by fixation at different time points to capture the progression of AQP2 movement. Differential centrifugation can be used to separate membrane fractions, with subsequent immunoblotting to detect changes in AQP2 distribution . A critical methodological consideration is ensuring that plasma membrane contamination is minimized in subcellular fractionation experiments, which can be verified by using biotinylation techniques to mark plasma membrane proteins .

What are the recommended protocols for immunoisolation of AQP2-containing vesicles?

For successful immunoisolation of AQP2-containing vesicles:

• Begin with tissue preparation, ideally using freshly isolated inner medullary collecting duct (IMCD) cells from rat kidneys

• Perform differential centrifugation to obtain a low-density membrane suspension (typically the 200,000 × g pellet)

• Use anti-AQP2 antibodies coupled to a solid support (such as magnetic beads or agarose) for immunoisolation

• Verify successful isolation through:

  • Immuno-gold electron microscopy to confirm AQP2 labeling of isolated vesicles

  • Immunoblotting with anti-AQP2 antibodies to confirm enrichment

  • Absence of plasma membrane markers if specifically isolating intracellular vesicles

This approach enables further characterization of AQP2-containing compartments through proteomic analysis, which has revealed that intracellular AQP2 resides primarily in endosomes, trans-Golgi network, and rough endoplasmic reticulum .

How can researchers distinguish between different intracellular AQP2 compartments?

Distinguishing between different intracellular AQP2 compartments requires identification of compartment-specific marker proteins. Proteomic analysis of immunoisolated AQP2-containing vesicles has revealed several key markers :

Notably, Rab3 (a marker for secretory vesicles) was not found by mass spectrometry or immunoblotting, suggesting a relative lack of AQP2 in secretory vesicles .

What are the potential pitfalls in interpreting AQP2 immunolocalization studies?

When interpreting AQP2 immunolocalization studies, researchers should be aware of several potential pitfalls:

• Fixation artifacts: Fixatives needed for high-quality structural preservation can markedly decrease the ability of AQP2 antibodies to recognize the target protein in electron microscopy studies

• Resolution limitations: Immunofluorescence with confocal microscopy lacks sufficient spatial resolution to identify AQP2 localization in subcellular compartments with certainty, even with double labeling using compartment-specific marker proteins

• Heterogeneity of AQP2-containing vesicles: Proteomic analysis has revealed that AQP2-containing vesicles are heterogeneous, residing in multiple compartments including endosomes, trans-Golgi network, and rough endoplasmic reticulum

• Dynamic trafficking considerations: AQP2 is constantly trafficking between intracellular compartments and the plasma membrane, meaning that localization patterns change based on physiological state and experimental conditions

To overcome these limitations, researchers should employ multiple complementary techniques and carefully control for physiological state and experimental conditions.

How can researchers effectively analyze contradictory data regarding AQP2 regulation?

When analyzing contradictory data regarding AQP2 regulation, researchers should consider:

• Species differences: AQP2 regulation may vary between species. While antibodies like AQP2 Antibody (E-2) can detect AQP2 from mouse, rat, and human origins , regulatory mechanisms might differ slightly between species

• Cell-type specificity: Primary cells vs. cell lines may show different regulatory patterns

• Experimental conditions: The phosphorylation state of AQP2 dramatically affects its localization and function, so differences in cell stimulation protocols can lead to apparently contradictory results

• Antibody specificity: Different antibodies may recognize different epitopes or conformational states of AQP2

• Quantification methods: Western blotting vs. immunofluorescence quantification can yield different results due to technical limitations

To address contradictions, researchers should directly compare experimental conditions, use multiple antibodies targeting different epitopes, employ both biochemical and imaging approaches, and carefully control for the phosphorylation state of AQP2.

How can AQP2 antibodies be utilized to study kidney pathophysiology in disease models?

AQP2 antibodies are invaluable tools for studying kidney pathophysiology in various disease models. For example, in gentamicin-induced kidney injury models, immunohistochemical staining using Anti-Aquaporin 2 Antibody (#AQP-002) has revealed changes in AQP2 expression patterns in the cortex, outer medulla, and inner medulla of rat kidneys following treatment . These studies help elucidate how nephrotoxic agents affect water handling in the kidney. Similarly, AQP2 antibodies can be used to study models of diabetes insipidus, where mutations in the AQP2 gene result in the excretion of large volumes of dilute urine .

Research protocols typically involve:

• Establishing appropriate disease models (genetic, pharmaceutical, or surgical)

• Collecting kidney tissue samples at relevant time points

• Processing tissues for immunohistochemistry or preparing membrane fractions for western blotting

• Using AQP2 antibodies to detect changes in expression level, localization, or phosphorylation state

• Correlating molecular findings with physiological parameters such as urine output and concentration

What experimental approaches can be used to study the relationship between AQP2 phosphorylation and trafficking?

Studying the relationship between AQP2 phosphorylation and trafficking requires specialized experimental approaches:

• Phosphorylation-specific antibodies: Using antibodies that specifically recognize phosphorylated forms of AQP2 at different sites (e.g., Ser256, Ser261, Ser264, Ser269)

• Pharmacological interventions: Using agents that affect cAMP levels or PKA activity to manipulate the phosphorylation state of AQP2

• Phosphomimetic mutations: Creating AQP2 constructs with mutations that either prevent phosphorylation (e.g., Ser to Ala) or mimic constitutive phosphorylation (e.g., Ser to Asp)

• Live-cell imaging: Using fluorescently tagged AQP2 constructs to monitor trafficking in real-time following stimulation with vasopressin

• Quantitative analysis: Measuring the ratio of membrane to cytoplasmic AQP2 under different conditions

These approaches can help elucidate how specific phosphorylation events regulate the intracellular trafficking and membrane insertion of AQP2, which is critical for water reabsorption in the kidney collecting duct.

What controls should be included when validating new AQP2 antibodies for research applications?

When validating new AQP2 antibodies, researchers should include the following controls:

• Blocking peptide controls: Preincubating the antibody with the immunizing peptide should abolish specific staining, as demonstrated with Anti-Aquaporin 2 Antibody (#AQP-002)

• Tissue specificity controls: Comparing staining patterns in tissues known to express AQP2 (e.g., kidney collecting ducts) versus tissues that do not express AQP2 (e.g., thin segments of the loop of Henle)

• Knockout/knockdown controls: Testing the antibody in tissues or cells where AQP2 expression has been genetically eliminated or reduced

• Multiple antibody validation: Comparing results from multiple antibodies targeting different epitopes of AQP2

• Cross-reactivity assessment: Testing the antibody against recombinant proteins or tissues from different species to confirm specificity and cross-reactivity as claimed by manufacturers

These validation steps are essential for ensuring that experimental findings reflect true AQP2 biology rather than artifacts related to antibody cross-reactivity or non-specific binding.

How might AQP2 antibodies contribute to emerging therapeutic strategies for water balance disorders?

AQP2 antibodies play a crucial role in developing therapeutic strategies for water balance disorders by:

• Enabling high-throughput screening of compounds that modulate AQP2 trafficking or function

• Allowing researchers to monitor therapeutic efficacy in preclinical models

• Providing tools for investigating potential off-target effects on water homeostasis

• Facilitating personalized medicine approaches by assessing AQP2 expression or trafficking defects in patient samples

• Contributing to the development of diagnostic tools for various forms of diabetes insipidus

Understanding AQP2 regulation is important for developing therapeutic strategies for kidney-related disorders and managing fluid balance in various clinical settings .

What methodological advances would enhance the study of AQP2 trafficking dynamics?

Several methodological advances would significantly enhance our understanding of AQP2 trafficking dynamics:

• Super-resolution microscopy techniques to overcome the resolution limitations of conventional confocal microscopy

• Advanced proteomics approaches to better characterize the protein composition of AQP2-containing vesicles during different trafficking stages

• CRISPR-based gene editing to create endogenously tagged AQP2 for live-cell imaging without overexpression artifacts

• Single-molecule tracking to follow individual AQP2 channels during trafficking events

• Correlative light and electron microscopy to link functional observations with ultrastructural details

• Advanced computational modeling of trafficking pathways based on experimental data